Patents by Inventor Jill E. Parker

Jill E. Parker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120021004
    Abstract: A new strain of Bacillus anthracis derived from the Sterne vaccine strain of Bacillus anthracis by growth on a high-nitrate-concentration, 3-amino-L-tyrosine growth medium.
    Type: Application
    Filed: May 25, 2007
    Publication date: January 26, 2012
    Inventors: Jill E. Parker, Johnathan L. Kiel, Homer Gifford, John L. Alls, Pedro J. Morales
  • Patent number: 8092988
    Abstract: A new strain of Bacillus anthracis derived from the Sterne vaccine strain of Bacillus anthracis by growth on a high-nitrate-concentration, 3-amino-L-tyrosine growth medium.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: January 10, 2012
    Assignee: The United States of America as represented by the Secretary of the Air Force
    Inventors: Jill E. Parker, Johnathan L. Kiel, Homer Gifford, John L. Alls, Pedro J. Morales, legal representative
  • Patent number: 7279320
    Abstract: A new strain of Bacillus anthracis derived from the Sterne vaccine strain of Bacillus anthracis by growth on a high-nitrate-concentration, 3-amino-L-tyrosine growth medium.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: October 9, 2007
    Assignee: United States as represented by the Secretary of the Air Force
    Inventors: Jill E. Parker, Johnathan L. Kiel, Homer Gifford, Pedro J. Morales, legal representative, John L. Alls, deceased
  • Patent number: 6878519
    Abstract: A PCR-based method for the identification of Bacillus anthracis is described. The method utilizes novel primer sets; designated 2Xlg3F (SEQ ID NO 3), 2Xlg3R (SEQ ID NO 4), 2Xlg3F2 (SEQ ID NO 5), 2Xlg3R2 (SEQ ID NO 6), 4XH1a2F (SEQ ID NO 7), and 4XH1a2R (SEQ ID NO 8).
    Type: Grant
    Filed: January 6, 2003
    Date of Patent: April 12, 2005
    Assignee: The United States of America as represented by the Secretary of the Air Force
    Inventors: Jill E. Parker, Johnathan L. Kiel
  • Patent number: 6326196
    Abstract: The cell line HeLa is transformed with the chromosomal insertion of the plasmid pSV2neoNR101, ATCC No. 69617. The transformed cells, HeLaNR1, produce diazoluminomelanin (DALM) intra cellularly when provided with nitrate, luminol and 3-amino-L-tyrosine•HC1 (3AT). The modified cells can be used to study mechanisms for radiofrequency and light radiation interactions with carcinoma of the cervix. The effects of drugs, hormones, and cytokines that affect the expression of nitric oxide synthase and its activity can also be studied to understand the effects of these materials on cervix cells.
    Type: Grant
    Filed: January 22, 2001
    Date of Patent: December 4, 2001
    Assignee: The United States of America as represented by the Secretary of the Air Force
    Inventors: Jill E. Parker, Johnathan L. Kiel
  • Patent number: 6303316
    Abstract: In a recognition complex system, nucleic acid ligands comprising random DNA sequences are operatively coupled to an organic semiconductor and distributed so as to form an array of recognition complexes. When an unknown chemical or biological analyte is applied to the array, the electrical and/or photochemical properties of one or more of the recognition complexes are altered upon binding of the nucleic acid ligand to the analyte. The degree to which the electrical and/or photochemical properties change is a function of the affinity of the nucleic acid ligand sequence for the analyte. The electrical and photochemical changes associated with the array, as a whole, can be used as a unique signature to identify the analyte.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: October 16, 2001
    Assignee: Conceptual Mind Works, Inc.
    Inventors: Johnathan L. Kiel, John G. Bruno, Jill E. Parker, John L. Alls, Charles R. Batishko, Eric A. Holwitt
  • Patent number: 6013520
    Abstract: The cell line EMT-6 are transformed with the chromosomal insertion of the plasmid pSV.sub.2 neoNR10.sub.1, ATCC No. 69617. The transformed cells, EMT-6/pSV.sub.2 neoNR10.sub.1, produce diazoluminomelanin (DALM) intracellularly when provided with nitrate, luminol and 3-amino-L-tyrosine.multidot.HCl (3AT). The modified cells can be used to study mechanisms for radiofrequency and light radiation interactions with breast tumor cells in vitro and in mice. The effects of drugs, hormones, and cytokines that affect the expression of nitric oxide synthase and its activity can also be studied to understand the effects of these materials on breast tumor cells.
    Type: Grant
    Filed: August 20, 1998
    Date of Patent: January 11, 2000
    Assignee: The United States of America as represented by the Secretary of the Air Force
    Inventors: Jill E. Parker, Johnathan L. Kiel
  • Patent number: 5902728
    Abstract: E. coli strain JM109 transfected with nitrate reductase gene containing plasmid pIC20RNR1.1 produces diazoluminomelanin when cultured in a medium containing nitrate, 3-amino-L-tyrosine and luminol, under suitable metabolic conditions.
    Type: Grant
    Filed: September 19, 1997
    Date of Patent: May 11, 1999
    Assignee: The United States of America as represented by the Secretary of the Air Force
    Inventors: Jill E. Parker, John L. Alls, Jonathan L. Kiel
  • Patent number: 5856108
    Abstract: There is provided a method for producing diazoluminomelanin (DALM) which comprises culturing in a medium containing nitrate, 3-amino-L-tyrosine (3-AT) and luminol under suitable metabolic conditions, a microorganism containing nitrate reductase.Also provided is a method for directly detecting microorganisms containing nitrate reductase or those into which nitrate reductase can be introduced by recombinant DNA technology, which comprises culturing the microorganism in a medium containing nitrate, 3-amino-L-tyrosine (3-AT) and luminol under suitable metabolic conditions, transferring the medium to a microtiter plate or tube coated with antibody or an antiligand to which the microorganism would specifically bind, washing the plate or tube and activating luminescence.Further, there is provided a method for producing diazomelanin (DM) which comprises culturing in a medium containing nitrate and 3-amino-L-tyrosine (3-AT) under suitable metabolic conditions, a microorganism containing nitrate reductase.
    Type: Grant
    Filed: October 21, 1991
    Date of Patent: January 5, 1999
    Assignee: The United States of America as represented by the Secretary of the Air Force
    Inventors: Johnathan L. Kiel, Jill E. Parker, Eric A. Holwitt, Harvey A. Schwertner
  • Patent number: 5464768
    Abstract: Mamammalian cell lines capable of enhanced nitrite production are by transfecting a murine macrophage or murine thymoma with barley nitrate reductase gene (NR).
    Type: Grant
    Filed: May 16, 1994
    Date of Patent: November 7, 1995
    Assignee: The United States of America as represented by the Secretary of the Air Force
    Inventors: Johnathan L. Kiel, Jill E. Parker, John G. Bruno
  • Patent number: 5156971
    Abstract: A diagnostic test for environmental bacillus which comprises the steps of inoculating an agar growth medium comprising a nitrate source, luminol and 3-amino-L-tyrosine (3AT) with the sample, incubating the inoculated medium and determining the presence of the bacillus. The novel medium preferably comprises potassium nitrate, luminol, 3-amino-L-tyrosine and trypticase soy agar. Antibiotics and/or a specific bacteriophage may be added to the medium surface in localized areas to show specific bacterial lysis for identification. The novel medium and the methods of this invention are suitable for the identification of B. anthracis.
    Type: Grant
    Filed: January 15, 1992
    Date of Patent: October 20, 1992
    Inventors: Johnathan L. Kiel, John L. Alls, Richard A. Weber, Jill E. Parker